Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid cardiovascular outcomes study in statin-intolerant patients
2016-003485-11Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and hypercholesterolemia comparing Bempedoic acid with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2016; status: completed.
02
Drugs
bempedoic acid
03
Conditions
cardiac morbidityhypercholesterolemia
Beyond the preview
Go deeper on 2016-003485-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003485-11.